| Literature DB >> 17961254 |
Zané Lombard1, Nicki Tiffin, Oliver Hofmann, Vladimir B Bajic, Winston Hide, Michèle Ramsay.
Abstract
BACKGROUND: Fetal alcohol syndrome (FAS) is a serious global health problem and is observed at high frequencies in certain South African communities. Although in utero alcohol exposure is the primary trigger, there is evidence for genetic- and other susceptibility factors in FAS development. No genome-wide association or linkage studies have been performed for FAS, making computational selection and -prioritization of candidate disease genes an attractive approach.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17961254 PMCID: PMC2194724 DOI: 10.1186/1471-2164-8-389
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Summary of criteria used to create a binary grid
| Glial cell | Apoptosis | Mental Retardation | All known human | |
| Neuron | Development | Growth | Microcephaly | imprinted genes |
| Fibroblast | Brain Development | Behaviour/Neurological | Craniofacial | |
| Neuroepithelium | Transport | Craniofacial | Hyperactivity | |
| Signal Transduction | Nervous | Growth Retardation | ||
| Embryogenesis | ||||
| Pre-Embryonic | ||||
| Embryonic | ||||
| Fetal | ||||
| TS18–9 Ectoderm | ||||
| TS10–13 Neural Ectoderm | ||||
| TS14–26 CNS | ||||
| TS28 CNS | ||||
| TS12–26 Head | ||||
| TS20–26 Cranium | ||||
1TS – Theiller stage: A term used to denote the stage of development of a mouse as described by Theiler in "The House Mouse: Atlas of Mouse Development" (Springer-Verlag, New York, 1989)
Selected top-ranked candidate genes for FAS identified using binary matrix filtering
| 1 | 17/29 | Fibroblast growth factor receptor 1 | 8p11.2 | Involved in limb induction, play a role in bone elongation modulation | |
| 2 | 16/29 | Msh homeobox homolog 1 gene | 4p16.3-p16.1 | Potential repressor function in cell cycle progression, transcription repressor | |
| 3 | 15/29 | Fibroblast growth factor receptor 2 | 10q26 | Involved in vertebral development, important regulator of bone formation and osteoblast activity | |
| 4 | 15/29 | Forkhead box G1B | 14q13 | Embryonic transcriptional regulator, playing a critical role in brain development | |
| 5 | 15/29 | Homeobox A1 | 7p15.3 | Involved in the placement of hindbrain segments in the proper location along the anterior-posterior axis during development | |
| 6 | 14/29 | Bone morphogenetic protein 4 | 14q22-q23 | Regulating myogenesis through dosage-dependent PAX3 expression in pre-myogenic cells, inducing apoptosis and chondrogenesis in the chick limb bud | |
| 7 | 14/29 | Fibroblast growth factor receptor 3 | 4p16.3 | Negative regulator of bone growth promotion, inhibition of chondrocyte proliferation and differentiation depending on devlopmental time | |
| 8 | 14/29 | Gnas complex locus | 20q13.2-q13.3 | Involved as modulators or transducers in various transmembrane signaling systems primarily mediating the differential effects of parathyroid hormone | |
| 9 | 14/29 | Paired box gene 6 | 11p13 | Key regulator of eye, pancreas, central nervous system development and regulator of glial precursors in the ventral neural tube |
1 Members of/linked to the MAPK signalling pathway
2 Members of/linked to the TGF-β signalling pathway
3Members of/linked to the Hedgehog signalling pathway
Figure 1The STRING network of known protein-protein interaction among the 78 top-ranked candidate genes for FAS. The network edges represent the predicted functional associations. Each different colour represents a different line of evidence: pink = experimental data, light blue = homology analysis and turquoise = functional association.
Known protein-protein interaction for the prioritized candidate genes obtained using STRING
| 0.747 | 0.8 | 0.949 | ||
| 0.935 | 0 | 0.935 | ||
| 0.912 | 0.9 | 0.991 | ||
| 0.937 | 0 | 0.937 | ||
| 0.935 | 0 | 0.935 | ||
| 0 | 0.9 | 0.9 | ||
| 0.935 | 0 | 0.935 | ||
| 0.747 | 0.9 | 0.974 | ||
| 0.997 | 0 | 0.997 | ||
| 0.935 | 0 | 0.935 | ||
| 0.938 | 0 | 0.938 | ||
| 0 | 0.9 | 0.9 | ||
| 0 | 0.9 | 0.9 | ||
| 0.935 | 0 | 0.935 | ||
| 0 | 0.9 | 0.9 | ||
| 0.03 | 0.9 | 0.903 | ||
| 0.983 | 0.9 | 0.998 | ||
| 0 | 0.9 | 0.9 | ||
| 0 | 0.9 | 0.9 | ||
| 0 | 0.9 | 0.9 | ||
The available evidence for the most significant interactions as well as the confidence score assigned for the interactions are shown
1 Members of/linked to the MAPK signalling pathway
2 Members of/linked to the TGF-β signalling pathway
3Members of/linked to the Hedgehog signalling pathway
Biological pathways significantly over-represented among the top-ranked candidate genes
| TGF-b signaling pathway | 9 | 0.0000067 | 0.00001 |
| Hedgehog signaling pathway | 7 | 0.000038 | 0.000036 |
| MAPK signaling pathway | 13 | 0.000078 | 0.0006 |
| Adherens junction | 7 | 0.00035 | 0.00051 |
| Cell cycle | 8 | 0.00036 | 0.0012 |
| Neurodegenerative disorders | 5 | 0.00075 | 0.0023 |
| Regulation of actin cytoskeletan | 9 | 0.0035 | 0.014 |
| Focal adhesion | 9 | 0.004 | 0.022 |
| Gap junction | 6 | 0.0059 | 0.0079 |
| Cytokine-cytokine receptor interaction | 9 | 0.011 | 0.0017 |
| Epithelial cell signaling in H. Pylori infection | 4 | 0.018 | 0.029 |
The gene count indicates how many genes from a particular pathway were present in the candidate gene list of 87 genes. Note that varying P-values were obtained depending on the background list used
1P-value obtained using the Homo sapiens gene list as a background list to the top-ranked candidate genes
2P-value obtained using the original candidate gene list as a background list to the top-ranked candidate genes
Promoter elements found to be enriched in the target promoter set relative to the background promoter set
| -1 MAZR | 11.5685 | 5.7 | 2.07 | 0.00009 | 0.00002 | 31 | 212 | 544 | 10255 | 0.002 |
| +1 MAZR | 5.6322 | 5.15 | 2.08 | 0.00005 | 0.00002 | 28 | 213 | 544 | 10255 | 0.033 |
| -1 TATA | 2.9231 | 16.36 | 9.76 | 0.00017 | 0.00010 | 89 | 1001 | 544 | 10255 | 0.002 |
| -1 TFII-I | 2.8865 | 18.2 | 10 | 0.00017 | 0.00011 | 99 | 1025 | 544 | 10255 | <0.001 |
| -1 MAZ | 2.6342 | 29.96 | 20.03 | 0.00040 | 0.00022 | 163 | 2054 | 544 | 10255 | <0.001 |
The criteria for selecting PE as enriched was that it has to appear in at least 5% of the target promoter sequences and to have over-representation index (ORI) of at least 2. PE that appear in statistically significant proportion in the target set are denoted by + in the ORI column.
Pairs of promoter elements found to be enriched in the target promoter set relative to the background promoter set
| -1 MZF1/+1 E2F | 17.1036 | 6.62 | 1.47 | 0.00007 | 0.00002 | 36 | 151 | 544 | 10255 | 0.000003 |
| -1 LEF1/-1 Pax-4 | 14.6726 | 6.62 | 1.77 | 0.00007 | 0.00002 | 36 | 182 | 544 | 10255 | 0.000254 |
| -1 C/EBP/+1 VDR | 10.1454 | 6.43 | 1.85 | 0.00006 | 0.00002 | 35 | 190 | 544 | 10255 | 0.002385 |
| +1 C/EBP/+1 VDR | 9.1022 | 6.99 | 2.42 | 0.00009 | 0.00003 | 38 | 248 | 544 | 10255 | 0.041880 |
| -1 MAZ/-1 VDR | 9.0220 | 9.19 | 2.89 | 0.00015 | 0.00005 | 50 | 296 | 544 | 10255 | 0.000012 |
| -1 MZF1/-1 MZF1 | 8.4560 | 5.51 | 1.6 | 0.00007 | 0.00003 | 30 | 164 | 544 | 10255 | 0.039710 |
| -1 ETF/-1 VDR | 7.6725 | 7.54 | 2.68 | 0.00011 | 0.00004 | 41 | 275 | 544 | 10255 | 0.023710 |
| -1 AP-2/-1 ETF | 6.8853 | 12.87 | 5.11 | 0.00023 | 0.00009 | 70 | 524 | 544 | 10255 | 0.000015 |
| -1 MAZ/+1 Sp1 | 6.4534 | 9.56 | 2.63 | 0.00012 | 0.00007 | 52 | 270 | 544 | 10255 | 0.000000 |
| -1 Spz1/-1 Spz1 | 6.0515 | 14.34 | 5.57 | 0.00021 | 0.00009 | 78 | 571 | 544 | 10255 | <0.00001 |
| -1 VDR/-1 Spz1 | 5.4345 | 14.34 | 6.54 | 0.00024 | 0.00010 | 78 | 671 | 544 | 10255 | 0.000429 |
| -1 ETF/-1 E2F | 5.4001 | 11.76 | 5.22 | 0.00020 | 0.00009 | 64 | 535 | 544 | 10255 | 0.007227 |
| -1 Spz1/-1 VDR | 5.2463 | 13.6 | 6.58 | 0.00025 | 0.00010 | 74 | 675 | 544 | 10255 | 0.013100 |
| -1 VDR/+1 ZF5 | 4.4308 | 14.15 | 6.59 | 0.00018 | 0.00009 | 77 | 676 | 544 | 10255 | 0.001322 |
The criteria for selecting pairs of PE as enriched was that it has to appear in at least 5% of the target promoter sequences and to have over-representation index (ORI) of at least 2. PE that appear in statistically significant proportion in the target set are denoted by + in the ORI column.
Figure 2The method of integrated literature- and data mining to identify an initial list of putative candidate genes.